Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,705.00INR
11:04am IST
Price Change (% chg)

Rs-28.95 (-1.06%)
Prev Close
Rs2,733.95
Open
Rs2,734.00
Day's High
Rs2,745.20
Day's Low
Rs2,701.55
Volume
2,909
Avg. Vol
35,232
52-wk High
Rs2,939.80
52-wk Low
Rs2,025.00

REDY.BO

Chart for REDY.BO

About

Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active... (more)

Overall

Beta: 0.43
Market Cap (Mil.): Rs463,924.50
Shares Outstanding (Mil.): 170.34
Dividend: 18.00
Yield (%): 0.66

Financials

  REDY.BO Industry Sector
P/E (TTM): 21.60 35.48 35.85
EPS (TTM): 126.11 -- --
ROI: 21.05 18.97 18.25
ROE: 26.30 19.75 19.12
Search Stocks

Dr. Reddy's gains as worries about spending ease

Reuters Market Eye - Shares of Dr. Reddy's Laboratories rise, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say.

30 Jun 2014

MARKET EYE-India's Dr. Reddy's gains as worries about spending ease

* Shares of India's Dr. Reddy's Laboratories up 1 percent, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say. * Dr. Reddy's said in its annual report filed with the U.S. Securities and Exchange Commission that the company would finance expansion plans through operating cash flow and through cash and other investments, and that the majority of

30 Jun 2014

MARKET EYE-Indian drugmakers hit by worries about Russia, Ukraine sales

* Shares in Indian drugmakers fall, with Dr Reddy's Laboratories down 1.9 percent, on concerns that sales in Russia and Ukraine will be hit given military tensions between the two countries. * Dr. Reddy's has the highest exposure to Russia and former Soviet republics, with the region comprising 14.5 percent of sales, Bank of America-Merrill Lynch says in a note dated on Monday. * Ranbaxy Laboratories Ltd and Glenmark Pharmaceuticals Ltd also have exposure to Russia and former Soviet republics,

04 Mar 2014

Dr Reddy's hits record high on migraine drug launch in U.S.

Reuters Market Eye - Shares in Dr Reddy's Laboratories rose as much as 2.1 percent to a record high on growing hopes about its U.S. business.

26 Feb 2014

Earnings vs. Estimates

Search Stocks